CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-07 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +67,171 | $15.85 | $1.1M | 1,572,130 |
| 2025-10-07 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +107,131 | $7.45 | $798K | 1,679,261 |
| 2025-10-07 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +180,859 | $3.85 | $696K | 1,860,120 |
| 2025-10-07 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −355,161 | $16.15 | $5.7M | 1,504,959 |
| 2025-10-07 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −67,171 | 987,357 | ||
| 2025-10-07 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −107,131 | 128,295 | ||
| 2025-10-07 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −180,859 | 6,276,523 | ||
| 2025-10-06 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +127,355 | $15.85 | $2.0M | 1,632,314 |
| 2025-10-06 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +24,900 | $7.45 | $186K | 1,657,214 |
| 2025-10-06 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +19,141 | $3.85 | $74K | 1,676,355 |
| 2025-10-06 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −171,396 | $16.34 | $2.8M | 1,504,959 |
| 2025-10-06 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −127,355 | 1,054,528 | ||
| 2025-10-06 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −24,900 | 235,426 | ||
| 2025-10-06 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −19,141 | 6,457,382 | ||
| 2025-09-28 | Pulik Richard CFO | Shares withheld for taxes | −2,341 | $15.17 | $36K | 389,508 |
| 2025-09-23 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −611,000 | $14.83 | $9.1M | 1,504,959 |
| 2025-09-22 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +462,374 | $3.85 | $1.8M | 2,432,141 |
| 2025-09-22 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +100,000 | $3.85 | $385K | 2,532,141 |
| 2025-09-22 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −316,182 | $14.99 | $4.7M | 2,215,959 |
| 2025-09-22 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −100,000 | $15.01 | $1.5M | 2,115,959 |
Page 18 of 29 · 570 trades